However, IGF1R targeting in cancer [63] has proven to be a consistently ineffective strategy in controlling tumor progression, as shown in 183 human clinical trials involving >12,000 patients across several tumor types (2003–2021) at a net cost estimated between $1.6–2.3 billion [64]. This evidence concerns the gene IGF1R and neoplasm.